TICKERNERD
Menu
NGNENGNEHealthcare · Biotechnology

NGNE Stock Forecast: Neurogene, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$28
−4.41% on the day

The 10 Wall Street analysts covering Neurogene, Inc. hold a median 12-month price target of $65 — +135.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 31 Oct 2026 — in the upper half.

Market cap
$551.3M
Ticker Nerd rank
58/ 100
Median analyst target
$65
Analysts covering
10
Revenue$0.0
Operating income−$36.7M
Net income−$34.5M
Free cash flow−$24.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+17.0%
1M
−1.0%
YTD
+33.7%
1Y
−16.9%
From 52W high
−35.7%
From 52W low
+68.3%
$16
$43
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

NGNE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Neurogene, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
58/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
82
Momentum
81
Accruals
78
Value
52
Size
51
Quality
49
Revisions
41
Growth
27
Volatility
21

Issuance (82): The share count has been shrinking and the company is not leaning on new borrowing.

Volatility (21): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NGNE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NGNE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$50$100$150Jan 26Apr 26Jul 26Oct 26NGNEHigh $166Median $65Low $46

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $46Median $65High $166

The green dot is the last close — the median target sits +135.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 2 moved it down.

DateFirmActionRatingTarget
28 Oct 2026HC Wainwright & Co.ReiteratesBuy$65
8 Oct 2026JP MorganInitiatesOverweight$60
8 Oct 2026JP MorganInitiatesOverweight—
12 Aug 2026Canaccord GenuityMaintainsBuy—
12 Aug 2026Canaccord GenuityMaintainsBuy$180 → $166
12 Aug 2026GuggenheimMaintainsBuy$69 → $81
12 Aug 2026GuggenheimMaintainsBuy—
12 Aug 2026HC Wainwright & Co.MaintainsBuy—
12 Aug 2026HC Wainwright & Co.MaintainsBuy$70 → $65
9 June 2026HC Wainwright & Co.ReiteratesBuy—
9 June 2026HC Wainwright & Co.ReiteratesBuy$70
6 Apr 2026Canaccord GenuityMaintainsBuy—
27 Feb 2026Canaccord GenuityInitiatesBuy—
26 Jan 2026LifeSci CapitalInitiatesOutperform—
13 Jan 2026HC Wainwright & Co.ReiteratesBuy—
13 Nov 2025HC Wainwright & Co.MaintainsBuy—
31 Oct 2025HC Wainwright & Co.MaintainsBuy—
9 Oct 2025HC Wainwright & Co.ReiteratesBuy—
17 June 2025Craig-HallumInitiatesBuy—
12 June 2025BMO CapitalMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

NGNE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NGNE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Neurogene, Inc. returned −16.9% against +12.4% for the S&P 500, dividends included.

NGNE vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26NGNES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NGNE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
3
Fundamentals

Neurogene, Inc. (NGNE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−6.5×

Cheaper than 92% of US stocks

Price / sales
—
Price / book
2.0×

Cheaper than 43% of US stocks

EV / EBITDA
−2.8×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−45.3%

Higher than 23% of US stocks

Return on assets
−28.0%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Neurogene, Inc. (NGNE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Neurogene, Inc. has a market value of $551.3M and an enterprise value of $334.3M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$111.1M.

  • Free cash flow in the twelve months to 30 June 2026: −$87.7M.

  • Shares outstanding: 15.8M.

  • Trailing P/E: −6.5×; forward P/E: −4.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Neurogene, Inc. employs 131 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 31 Oct 2026

Data provided by Twelve Data

Peers

NGNE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NGNENeurogene, Inc.$551.3M58
PBYIPuma Biotechnology, Inc.$531.3M90
DRUGBright Minds Biosciences, Inc.$535.1M41
ENTXEntera Bio Ltd.$554.1M52
OCSOculis Holding AG$509.9M27
ETRAElectra Therapeutics, Inc.$508.4M1
GYREGyre Therapeutics, Inc.$507.8M48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Neurogene, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest NGNE news & analysis

Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome

Business Wire · 27 Oct 2026positive

Neurogene said it will present new preclinical data on its NGN-401 gene therapy program for Rett syndrome at the ESGCT 33rd Annual Congress, scheduled for October 27–30, 2026, in Hamburg. The company expects the data to further validate the therapy’s differentiated design.

Why it matters — The presentation will provide NGNE watchers with an update on preclinical evidence for its Rett syndrome gene therapy program.

Neurogene Announces Upcoming Presentations Highlighting Key Differentiators of NGN-401 for Rett Syndrome at the ESGCT 33rd Annual Congress

Business Wire · 20 Oct 2026positive

Neurogene said it will present data from its NGN-401 gene therapy program for Rett syndrome at the ESGCT 33rd Annual Congress, scheduled for October 27–30, 2026, in Hamburg. The company said new preclinical data will address two important topics, though the excerpt does not specify them.

Why it matters — The presentation will provide an opportunity for NGNE watchers to learn more about the preclinical NGN-401 program.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 5 Oct 2026neutral

Neurogene announced that its Compensation Committee approved non-qualified stock options for an aggregate of 8,340 shares of common stock, granted to five new employees on October 5, 2026, under Nasdaq Listing Rule 5635(c)(4).

Why it matters — The inducement grants indicate the company is adding new staff, which could signal ongoing operational expansion for NGNE.

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Business Wire · 8 Sept 2026neutral

Neurogene Inc. announced that its management will participate in the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, including a fireside chat and investor meetings. A live webcast of the fireside chat will be accessible.

Why it matters — The company's participation provides NGNE watchers an opportunity to hear from management and engage in investor meetings at a major investment conference.

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 4 Sept 2026neutral

Neurogene's Compensation Committee approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of common stock to two new employees on September 1, 2026, as inducement grants under Nasdaq Listing Rule 5635(c)(4).

Why it matters — NGNE watchers would care because this discloses a routine equity-based compensation action tied to hiring, which is a standard administrative disclosure rather than a reflection of company performance.

FAQ

Frequently asked questions about NGNE stock

What is the NGNE stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Neurogene, Inc. have a median 12-month price target of $65, with estimates ranging from $46 to $166. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NGNE stock a buy right now?

Of the 10 analysts covering Neurogene, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Neurogene, Inc. 58 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NGNE?

As at 31 Oct 2026, Neurogene, Inc. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (82 of 100).

Will NGNE stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +135.9% from the last close, and Ticker Nerd's factor model ranks Neurogene, Inc. 58 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NGNE stock forecast for 2030?

No analyst covering Neurogene, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NGNE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $166 over the next 12 months.

How has NGNE stock performed over the past year?

Neurogene, Inc. returned -16.9% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Neurogene, Inc. do?

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases.

What is the latest news on NGNE?

The most recent item we track (Business Wire, 27 Oct 2026): "Neurogene Presents New Data at ESGCT Congress that Reinforce Key Differentiators of NGN-401 Gene Therapy for Rett Syndrome". Neurogene said it will present new preclinical data on its NGN-401 gene therapy program for Rett syndrome at the ESGCT 33rd Annual Congress, scheduled for October 27–30, 2026, in Hamburg. The company expects the data to further validate the therapy’s differentiated design.

Company

About Neurogene, Inc.

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Its current pipeline centers on gene therapy programs designed to address severe disorders such as Rett syndrome and CLN5 Batten disease, with candidates that use adeno-associated virus delivery and proprietary transgene regulation technology to control gene expression in the central nervous system. Neurogene’s work is aimed at treating conditions with significant unmet medical need, where conventional approaches have limited impact on the underlying cause of disease. The company also operates gene therapy manufacturing capabilities to support clinical development and production of its programs. Headquartered in New York, Neurogene Inc. is part of the broader biotechnology and rare-disease therapeutics market, where it contributes to the advancement of precision genetic medicine for devastating neurological disorders.

CEO Dr. Rachel L. McMinn Ph.D. · 131 employees · United States · https://www.neurogene.com